Αρχική World News Plasma Lipid Biomarker PCPro Associated with Shorter OS and Earlier Clinical Progression... World News Plasma Lipid Biomarker PCPro Associated with Shorter OS and Earlier Clinical Progression in Patients with Metastatic Hormone-Sensitive Prostate Cancer Από Ogkologos - 27 Μαΐου, 2025 414 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a post-hoc analysis of the ENZAMET study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR The Lung Immune Prognostic Index May Indicate Response to Immune Checkpoint... 9 Δεκεμβρίου, 2020 Adding Lenvatinib to Pembrolizumab Does Not Provide Additional Benefit in Patients... 10 Σεπτεμβρίου, 2025 For the RTOG 9408, and this randomized 1,979 patients so you... 19 Ιουλίου, 2023 Subcutaneous Daratumumab Monotherapy for Patients with High-Risk Smoldering Multiple Myeloma 18 Δεκεμβρίου, 2024 Φόρτωση περισσοτέρων HOT NEWS Preclinical Study May Have Found New Treatment Option for Triple-Negative Breast... Adolescent and Young Adult Cancer Survivors Face More Co-morbidity in Later... Man Gets His First Haircut In 15 Years To Join The... ESMO Congresses in March: Sarcoma and Rare Cancers Congress and European...